Its licensing status can be verified via the MHRA's products database (products.mhra.gov.uk), the EMA's medicines pipeline (ema.europa.eu), and the FDA's Drugs@FDA database (fda.gov)
We have been successfully using GLP-1s for years at our clinic in conjunction with our metabolic health program, focusing on hormone health, food, sleep, and exercise
New findings from the landmark SELECT trial reveal that semaglutides cardiovascular benefits are only partly explained by reductions in waist size, suggesting broader protective effects beyond fat loss
The reason we say this is a marketing scheme rather than accurate promises is because: The research findings only apply to animal models and no studies demonstrating efficacy in human models
10,32-34 Obesity has been recognized as the single most important factor in the epidemic increase in T2DM worldwide